The Priority Review

Clinical trials Brief

Biogen presents new two-year data from Phase 2 CELIA study of diranersen

Biogen reported a 38% slowing of decline at two years on CDR-SB with the lowest dose of diranersen, up from 26% at 18 months. No new safety signals were reported for that dose.

Primary source

Company press release (PR Newswire), November 18, 2026

New Diranersen Data at CTAD Mark Continued Progress Toward Combination Therapies for Alzheimer's, Says the ADDF

Read the source: New Diranersen Data at CTAD Mark Continued Progress Toward Combination Therapies for Alzheimer's, Says the ADDF prnewswire.com

Machine-summarized from the source above; not independently reported. How we use automation